• 1. An ion-gating multinanochannel system based on a copper-responsive self-cleaving DNAzyme?
  Yang Chen,Di Zhou,Zheyi Meng,Jin Zhai Chem. Commun., 2016,52, 10020-10023
• 2. An apparatus for determining small amounts of alchohol in sour milk and urine
  Analyst, 1964,89, 272-275
• 3. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 4. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 5. An artificial photosynthetic system for photoaccumulation of two electrons on a fused dipyridophenazine (dppz)–pyridoquinolinone ligand?
  Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines

Recent Advances in the Application of 4-Piperidinecarboxaldehyde, 1-cyclopentyl- (CAS: 753028-96-5) in Chemical Biology and Pharmaceutical Research

The compound 4-Piperidinecarboxaldehyde, 1-cyclopentyl- (CAS: 753028-96-5) has recently garnered significant attention in chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This heterocyclic aldehyde serves as a crucial building block in the synthesis of various bioactive molecules, particularly in the design of kinase inhibitors and GPCR-targeting compounds. Recent studies have highlighted its role as a key intermediate in the preparation of potential therapeutics for neurological disorders and cancer.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 753028-96-5 in the synthesis of novel cyclin-dependent kinase (CDK) inhibitors. Researchers utilized this piperidine derivative as a core scaffold to develop compounds showing nanomolar potency against CDK4/6, with improved selectivity profiles compared to existing FDA-approved inhibitors. The structural flexibility offered by the cyclopentyl substitution at the 1-position was found to be critical for optimizing binding interactions in the ATP-binding pocket.

In neuropharmacology, recent work has explored 4-Piperidinecarboxaldehyde, 1-cyclopentyl- as a precursor for sigma receptor ligands. A 2024 publication in ACS Chemical Neuroscience reported the development of σ1 receptor modulators derived from this compound, showing promising results in animal models of neuropathic pain. The researchers noted that the cyclopentyl moiety contributed to enhanced blood-brain barrier penetration while maintaining favorable metabolic stability.

From a synthetic chemistry perspective, advancements have been made in the production and purification of 753028-96-5. A recent patent (WO2023124567) describes an improved catalytic process for its synthesis, achieving higher yields (85-90%) and purity (>99%) compared to traditional methods. This development is particularly significant for scaling up production while maintaining cost-effectiveness for pharmaceutical applications.

The compound's potential in targeted drug delivery systems has also emerged as an active research area. Studies have functionalized 4-Piperidinecarboxaldehyde, 1-cyclopentyl- with various targeting moieties, creating prodrugs that demonstrate tissue-specific activation. Recent in vitro and in vivo data suggest these derivatives may reduce off-target effects while maintaining therapeutic efficacy, particularly in oncology applications.

Looking forward, the unique chemical properties of 753028-96-5 continue to inspire novel applications. Current research directions include its incorporation into PROTAC molecules for targeted protein degradation and as a component of covalent inhibitors for challenging therapeutic targets. The compound's balanced lipophilicity and molecular geometry make it particularly valuable for addressing current challenges in drug discovery, such as achieving selectivity among closely related protein isoforms.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)